These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18488008)

  • 1. Stopping malaria parasites dead in their tracks.
    Doerig CD
    Nat Chem Biol; 2008 Jun; 4(6):334-5. PubMed ID: 18488008
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.
    Kato N; Sakata T; Breton G; Le Roch KG; Nagle A; Andersen C; Bursulaya B; Henson K; Johnson J; Kumar KA; Marr F; Mason D; McNamara C; Plouffe D; Ramachandran V; Spooner M; Tuntland T; Zhou Y; Peters EC; Chatterjee A; Schultz PG; Ward GE; Gray N; Harper J; Winzeler EA
    Nat Chem Biol; 2008 Jun; 4(6):347-56. PubMed ID: 18454143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmodium gametocyte inhibition identified from a natural-product-based fragment library.
    Vu H; Roullier C; Campitelli M; Trenholme KR; Gardiner DL; Andrews KT; Skinner-Adams T; Crowther GJ; Van Voorhis WC; Quinn RJ
    ACS Chem Biol; 2013 Dec; 8(12):2654-9. PubMed ID: 24079418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).
    Chapman TM; Osborne SA; Bouloc N; Large JM; Wallace C; Birchall K; Ansell KH; Jones HM; Taylor D; Clough B; Green JL; Holder AA
    Bioorg Med Chem Lett; 2013 May; 23(10):3064-9. PubMed ID: 23570789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
    Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational and experimental elucidation of Plasmodium falciparum phosphoethanolamine methyltransferase inhibitors: Pivotal drug target.
    Singh J; Vijay S; Mansuri R; Rawal R; Kadian K; Sahoo GC; Kumar M; Sharma A
    PLoS One; 2019; 14(8):e0221032. PubMed ID: 31437171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials.
    González-Bacerio J; Fando R; del Monte-Martínez A; Charli JL; Chávez Mde L
    Curr Drug Targets; 2014; 15(12):1144-65. PubMed ID: 25341419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Nitro styrylquinoline is an antimalarial inhibiting multiple stages of Plasmodium falciparum asexual life cycle.
    Roberts BF; Zheng Y; Cleaveleand J; Lee S; Lee E; Ayong L; Yuan Y; Chakrabarti D
    Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):120-129. PubMed ID: 28285258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodium kinases as targets for new-generation antimalarials.
    Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
    Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The exoneme helps malaria parasites to break out of blood cells.
    Janse CJ; Waters AP
    Cell; 2007 Dec; 131(6):1036-8. PubMed ID: 18083092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. That was then but this is now: malaria research in the time of an eradication agenda.
    Kappe SH; Vaughan AM; Boddey JA; Cowman AF
    Science; 2010 May; 328(5980):862-6. PubMed ID: 20466924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum.
    Kortagere S; Welsh WJ; Morrisey JM; Daly T; Ejigiri I; Sinnis P; Vaidya AB; Bergman LW
    J Chem Inf Model; 2010 May; 50(5):840-9. PubMed ID: 20426475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence polymorphisms in pfcrt are strongly associated with chloroquine resistance in Plasmodium falciparum.
    Chen N; Russell B; Staley J; Kotecka B; Nasveld P; Cheng Q
    J Infect Dis; 2001 May; 183(10):1543-5. PubMed ID: 11319698
    [No Abstract]   [Full Text] [Related]  

  • 14. Metalloaminopeptidases of the Protozoan Parasite
    Mills B; Isaac RE; Foster R
    J Med Chem; 2021 Feb; 64(4):1763-1785. PubMed ID: 33534577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Plasmodium falciparum protease inhibitors in the past decade (2002-2012).
    Pérez B; Teixeira C; Gomes JR; Gomes P
    Curr Med Chem; 2013; 20(25):3049-68. PubMed ID: 23514416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to antimalarial compounds: methods and applications.
    Witkowski B; Berry A; Benoit-Vical F
    Drug Resist Updat; 2009; 12(1-2):42-50. PubMed ID: 19285915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malaria Hybrids: A Chronological Evolution.
    Marella A; Verma G; Shaquiquzzaman M; Khan MF; Akhtar W; Alam MM
    Mini Rev Med Chem; 2019; 19(14):1144-1177. PubMed ID: 30887923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting malaria with specific CDK inhibitors.
    Geyer JA; Prigge ST; Waters NC
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parasitology. Drugs to combat tropical protozoan parasites.
    Gelb MH; Hol WG
    Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767
    [No Abstract]   [Full Text] [Related]  

  • 20. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.